The new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice
|
|
- Sydney Day
- 5 years ago
- Views:
Transcription
1 ... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol Education Program call for more aggressive lowering of the level of low-density lipoprotein (LDL) cholesterol and a significant increase in the number of patients eligible for therapy that lowers the level of LDL. Despite the efficacy of statins in lowering the LDL level and in reducing the risk of a coronary event or stroke, other cholesterol-lowering therapies are needed. Some patients are unable to tolerate statins or are not candidates for statin therapy because of liver enzyme abnormalities, age, a preference for nonsystemic therapy, or a modestly elevated LDL level. For those patients, bile acid sequestrants, intestinal bile acid transport inhibitors, acyl coenzyme A:cholesterol acyltransferase inhibitors, and a number of nonselective cholesterol absorption inhibitors are alternative treatments. However, those agents vary in their effectiveness in reducing the level of LDL. Their use often does not reduce the LDL level to the extent desired or is compromised by patients poor compliance with therapy because of inconvenient dosing or unpleasant side effects. Ezetimibe, the first selective inhibitor of intestinal cholesterol absorption, is a promising alternative to the agents listed above. When ezetimibe is used either as monotherapy or in combination with a statin, once-daily dosing reduces the level of LDL by an average of 18%. The new guidelines issued in 2001 by the National Cholesterol Education Program s (NCEP) Adult Treatment Panel (ATP III) differ in several significant ways from previous recommendations and, if followed by all practicing physicians, would mark a major change in the management of dyslipidemia in the United States. In the new guidelines, type 2 diabetes is classified as a coronary heart disease (CHD) risk equivalent, patients with 2 or more major risk factors for CHD are classified as high risk, and a lower level of low-density lipoprotein (LDL) is recommended as the treatment goal for patients at high, moderate, or low risk for CHD. 1 Those recommendations greatly increase the number of Americans eligible for LDL-lowering therapy. According to the new ATP III guidelines, those with CHD or other clinical forms of atherosclerotic disease, type 2 diabetes, or multiple risk factors that confer a 10-year risk of a coronary event that exceeds 20% should receive the most aggressive therapy, which is that of lowering the level of LDL to < 100 mg/dl. The LDL level recommended for those patients in previous NCEP guidelines was < 130 mg/dl. 1 The new guidelines also indicate that the LDL level should be lowered to < 130 mg/dl (a reduction from the prior cutpoint of < 160 mg/dl) in patients at moderate risk for a coronary event (those with 2 or more risk factors that confer a 10-year risk of 10% to 20% for a coronary event) and that it should be reduced to < 160 mg/dl (rather than the prior cutpoint of < 190 mg/dl) in those with a 10- year risk of less than 10%. 1 The Efficacy of Statins in Preventing a Coronary Event The statins are very effective and relatively safe in reducing the level of LDL and CHD-related morbidity and mortality S40 THE AMERICAN JOURNAL OF MANAGED CARE FEBRUARY 2002
2 Future Outlook: Changing Perspectives on Best Practice rates. That effectiveness has led many physicians to believe that there is little need for other lipid-modifying therapies. Although statins are readily available and effective, they do not meet the needs of many patients who require lipid-lowering therapy. It is essential that effective alternatives to statin therapy be available for those patients. For example, some patients cannot tolerate initial therapy with statins because of adverse side effects; others can tolerate a low dose of statins but not dose escalation. Some patients require a modest reduction in their level of LDL, some prefer nonsystemic therapy, others cannot achieve their target level of LDL as a result of statin monotherapy, and those with an elevated level of liver enzymes are not candidates for statin therapy. Many physicians are reluctant to prescribe statins for younger men and women who will require long-term therapy, and statins should not be prescribed for women who are pregnant or actively trying to become pregnant. Alternatives to Statin Monotherapy and Complementary Therapies Several alternatives and complements to statin monotherapy are currently available, and other potential agents and protocols are being investigated in clinical studies. Alternative agents exert an LDL-lowering effect primarily in the liver or the intestines. Combination therapy with agents that have complementary mechanisms of action can be very efficacious in further reducing LDL cholesterol and improving other aspects of the lipid profile. Niacin and Microsomal Triglyceride Transfer Protein Inhibitors An LDL-lowering effect in the liver is also produced by niacin and inhibitors of microsomal triglyceride transfer protein (MTP), a critical intracellular protein required for the development of nascent very-low-density lipoprotein (VLDL), which is the precursor of LDL. Niacin reduces the hepatic production of VLDL through mechanisms of action that are not completely understood. MTP inhibitors also lower the level of LDL by reducing VLDL secretion from the liver. Although MTP inhibitors have been investigated for some time, it is unclear whether they will ever be used clinically. Niacin is frequently used in combination with statins to lower the level of LDL even further. An observational study of an extended-release form of niacin indicated that 1 g of niacin added to a statin provided an additional 18% to 20% reduction in the level of LDL in patients who could not achieve a target LDL level while receiving statin monotherapy. 2 However, niacin can produce side effects that decrease its tolerability, and it is unlikely to be a long-term solution for patients who require further reduction in their level of LDL. Bile Acid Sequestrants Bile acid sequestrants are among several classes of agents that exert their effects primarily in the intestine, where lipids are packaged into chylomicrons and converted into chylomicron remnants that are ultimately taken up by the liver. Bile acid sequestrants have been available for many years. They bind bile acids, promote their excretion, and reduce their reuptake; reduce the enterohepatic cholesterol pool; upregulate LDL receptor activity in the liver and the clearance of LDL; and ultimately reduce the LDL plasma level. A new bile acid sequestrant, colesevelam, has multiple areas for bile acid binding, and 1 molecule of colesevelam can bind more bile acid than does 1 molecule of cholestyramine. As a result, the pill size of colesevelam is much smaller than that of cholestyramine. However, at least 3.8 g (6 pills per day) of colesevelam are required daily to produce a reasonable decrease in the level of LDL. According to a study in which monotherapy with colesevelam was evaluated, the standard daily dose of 3.8 g lowered the level of LDL in patients with moderate hypercholesterolemia by about 16%, produced a modest increase in the level of high-density lipoprotein (HDL), and VOL. 8, NO. 2, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S41
3 PRESENTATIONS Table 1. Case 1: A Young Man with Hypertension Age 34 years LDL level 176 mg/dl HDL level 34 mg/dl Risk 0 to 1 risk factor Initial therapy: Dietary modification and exercise for 3 months LDL level 162 mg/dl HDL level 36 mg/dl goal of < 160 mg/dl Options: A statin or monotherapy with ezetimibe 10 mg/day Option chosen: Monotherapy with ezetimibe Ezetimibe monotherapy for 3 months LDL level 128 mg/dl HDL level 40 mg/dl HDL = high-density lipoprotein; LDL = low-density lipoprotein. increased the level of triglycerides by about 10%. 3 Bile acid sequestrants such as colesevelam can be used in combination with statins in patients for whom statin monotherapy does not produce the desired level of LDL. Although bile acid sequestrants are relatively safe, the high pill burden of colesevelam and the inconvenient dosing of cholestyramine and colestipol reduce compliance and ultimately limit the effectiveness of those agents in monotherapeutic and combination regimens. Intestinal Bile Acid Transport Inhibitors Another potential approach to lowering the level of LDL is the use of intestinal bile acid transport (ibat) inhibitors, which are molecular compounds that directly inhibit the binding and transport of bile acids from the lumen of the intestine into the enterocyte, inhibit the uptake of bile acids and promote their excretion, and upregulate LDL receptor activity. These effects are conceptually related to those of bile acid sequestrants in that they decrease the enterohepatic circulation of bile acids and their return to the liver. The ibat inhibitors are currently being investigated in clinical trials and may be feasible alternatives to other therapies that lower the level of LDL. Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitors The use of acyl coenzyme A:cholesterol acyltransferase (ACAT) inhibitors is also effective in lowering the level of LDL. Because ACAT is required within the intestinal enterocyte to promote the esterification of free cholesterol and the transport of the ester, the inhibition of ACAT would theoretically reduce cholesterol absorption and ultimately reduce the level of LDL. The ACAT inhibitor avasimibe has been investigated in clinical trials. Plant Sterols and Stanols Plant sterols and stanols are functional foods that are available in health food stores and supermarkets. At a relatively high dose, they lower the level of LDL by interfering with the generation of micelles required for efficient cholesterol absorption. According to the results of a meta-analysis of 16 trials evaluating the effects of dietary phytosterols, those compounds reduced the LDL levels in patients with moderate hypercholesterolemia by a mean of 13%. 4 Although plant sterols and stanols are usually well tolerated, they must be taken 3 times per day to be effective. However, they are an alternative to statin therapy for patients who want to avoid systemic therapy and require only a minimal reduction in the level of LDL cholesterol and are willing to comply with the dosing regimen. Selective Cholesterol Absorption Inhibitors Ezetimibe, the first selective cholesterol absorption inhibitor, is now being investigated in clinical trials. At a dose of S42 THE AMERICAN JOURNAL OF MANAGED CARE FEBRUARY 2002
4 Future Outlook: Changing Perspectives on Best Practice Table 2. Case 2: A Postmenopausal Woman with Hypertension and a Family History of Premature Coronary Disease Age 55 years LDL level 202 mg/dl HDL level 39 mg/dl Risk 2+ risk factors Initial therapy: Atorvastatin 10 mg/day for 3 months LDL level 137 mg/dl HDL level 42 mg/dl goal of < 130 mg/dl Options: Escalation of statin dose or combination therapy with starting dose of statin plus ezetimibe 10 mg/day Option chosen: Combination therapy Combination therapy for 3 months LDL level 118 mg/dl HDL = high-density lipoprotein; LDL = low-density lipoprotein. 10 mg/day, it reduces the level of LDL by about 18% in monotherapeutic and combination regimens and is safe and well tolerated. It also increases the level of HDL, modestly lowers the level of triglycerides, and requires only oncedaily dosing. 5 The selective inhibition of cholesterol by ezetimibe suggests that this agent interferes with the transport of cholesterol across the brush border into the intestinal epithelial cell, a key step in the absorption of cholesterol. As a therapeutic alternative to statins, ezetimibe 10 mg/day appears to have great potential for use in clinical practice. As illustrated in the 3 cases described in this presentation (Tables 1 to 3), ezetimibe is suitable as a monotherapy for patients at low risk for CHD who require only a modest reduction in their LDL level, and it can be used in a combination regimen for patients at moderate or high risk for a cardiovascular event. Table 3. Case 3: A Middle-Aged Man with Type 2 Diabetes Age 56 years LDL level 183 mg/dl HDL level 36 mg/dl Risk CHD risk equivalent Initial therapy: Simvastatin 20 mg/day for 3 months LDL level 141 mg/dl HDL level 39 mg/dl goal of < 100 mg/dl Options: Escalation of statin dose or escalation of statin dose plus addition of ezetimibe 10 mg/day Option chosen: Escalation of statin dose Simvastatin 80 mg/day for 3 months LDL level 120 mg/dl HDL level 41 mg/dl Additional therapy still needed to reach LDL goal of < 100 mg/dl Options: Simvastatin 80 mg/day plus addition of ezetimibe 10 mg/day Combined therapy with high-dose simvastatin and ezetimibe for 3 months LDL level < 100 mg/dl CHD = coronary heart disease; HDL = high-density lipoprotein; LDL = low-density lipoprotein. Conclusion Statins are very effective in lowering the level of LDL and reducing the morbidity and mortality caused by CHD. Despite that success, those agents are not appropriate for all patients who must lower their LDL level. Furthermore, not all patients can achieve LDL goals on statin monotherapy. Therefore, alternative and/or additional therapies are needed. Selective cholesterol absorption inhibitors such as ezetimibe appear to be safe, effective, and well tolerated, and can also be used in combination with statins to lower the level of LDL. VOL. 8, NO. 2, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S43
5 PRESENTATIONS... REFERENCES Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel III). JAMA 2001;285: Wolfe ML, Vartranian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001;87: Insull W Jr, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: A 24-week randomized controlled trial. Mayo Clin Proc 2001;76: Moghadasian MH, Frolich JJ. Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: Clinical and experimental evidence. Am J Med 1999;107: Merck/Schering-Plough Pharmaceuticals; North Wales, PA. Data on file. S44 THE AMERICAN JOURNAL OF MANAGED CARE FEBRUARY 2002
... CPE/CNE QUIZ... CPE/CNE QUESTIONS
CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationLipoprotein Formation, Structure and Metabolism: Cholesterol Balance and the Regulation of Plasma Lipid Levels
Lipoprotein Formation, Structure and Metabolism: Balance and the Regulation of Plasma Lipid Levels David E. Cohen, MD, PhD Director of Hepatology, Gastroenterology Division, Brigham and Women s Hospital
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationCoronary heart disease is the leading cause of death in
PHARMACOLOGY NOTES Ezetimibe (Zetia): a new type of lipid-lowering agent JIGNA PATEL, PHARMD CANDIDATE, VALERIE SHEEHAN, PHARMD, AND CHERYLE GURK-TURNER, RPH Coronary heart disease is the leading cause
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationCoronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines
the osteopathic physician. The treatment approach involves therapeutic lifestyle changes with diet, exercise, and weight loss. It requires regular, careful monitoring of serum cholesterol levels. The new
More informationAchieving Lipid Goals: 2008 Update. Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy
Achieving Lipid Goals: 2008 Update Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy Discuss relationship between lipid values and coronary events Evaluate clinical
More informationIn May 2001, the National Cholesterol. Effective Management of Patients With Dyslipidemia REPORT. Robert J. Lipsy, PharmD
REPORT Effective Management of Patients With Dyslipidemia Robert J. Lipsy, PharmD Abstract Coronary heart disease (CHD) is the leading cause of morbidity and mortality in the United States. A direct relationship
More informationANSC/NUTR 618 LIPIDS & LIPID METABOLISM The LDL Receptor, LDL Uptake, and the Free Cholesterol Pool
ANSC/NUTR 618 LIPIDS & LIPID METABOLISM The, LDL Uptake, and the Free Cholesterol Pool I. Michael Brown and Joseph Goldstein A. Studied families with familial hypercholesterolemia. B. Defined the relationship
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationAnti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anti Hyperlipidemic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Lipoproteins Macromolecular complexes in the blood that transport lipids Apolipoproteins
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationClinical Approach to Achieving Treatment Targets: Case Vignette Discussion
Clinical Approach to Achieving Treatment Targets: Case Vignette Discussion Om P. Ganda, MD; Kirit Tolia, MD, FACE Postcardiac Follow-up in a 66-Year-Old Man Slide 1. Dr. Ganda: Now we will present a case
More informationCombined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia
European Heart Journal (2003) 24, 685 689 Editorial Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia James Shepherd * Institute of Biochemistry, Royal Infirmary,
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationImbalances in lipid components
Drugs for Dyslipidemia Vivien Gam, Pharm.D. 1 Dyslipidemia Imbalances in lipid components High total cholesterol High LDL cholesterol Low HDL cholesterol High triglycerides Significant risk factor for
More informationUnit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins
Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationTuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316
Ambulatory Care PRN Focus Session New Developments in Hypertension and Dyslipidemia Management Activity No. 0217-0000-11-101-L01-P (Application-Based Activity) Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention
More informationSupplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationPodcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam
Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam Howard J. Sachs, MD www.12daysinmarch.com Email: Howard@12daysinmarch.com Podcast (Video Recorded
More informationAcetyl CoA HMG CoA Mevalonate (C6) Dimethylallyl Pyrophosphate isopentenyl Pyrophosphate (C5) Geranyl Pyrophosphate (C10) FarnesylPyrophosphate (C15) Squalene (C30) Lanosterol (C30) 7 Dehydrocholesterol
More informationLipid Management: Tools for Getting to the Goal
... PRESENTATIONS... Lipid Management: Tools for Getting to the Goal Based on a presentation by James M. McKenney, PharmD Presentation Summary The treatment of hypercholesterolemia in the United States
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,
More informationCardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationIntroduction Hyperlipidemia hyperlipoproteinemia Primary hyperlipidemia (Familial) Secondary hyperlipidemia (Acquired)
Introduction Hyperlipidemia, or hyperlipoproteinemia, is the condition of abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Hyperlipidemias are divided in primary and secondary
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More informationDyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Dyslipidemia and HIV Heidi Crane, MD, MPH Madison Metabolic Clinic Associate Professor UW Department of Medicine Presentation prepared by: Heidi Crane, MD,
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationZetia (Ezetimibe) Drug Monograph. Clinical clerkship Students (Week 1)
Zetia (Ezetimibe) Drug Monograph Clinical clerkship Students (Week 1) Fan Sheung Yin Chan Wai Lok Lau Man Pong Li Kwan Lam Chau Chung Yan Wong Yi Man Law Wing Yan Tsang Chun Man Li Wing Suen Cynthia Ho
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationManaging Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus
Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationFocus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013
Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013 Conflicts CMO for The FH Foundation Pre-talk quiz What is cascade screening? 1. screening all family members 2.
More information10/1/2008. Therapy? Disclosure Statement
What s New in Lipid Therapy? Brooke Hudspeth, PharmD Diabetes Care Kroger Pharmacy Disclosure Statement In accordance with policies set forth by the Accreditation Council for Continuing Medical Education
More informationTuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316
Ambulatory Care PRN Focus Session New Developments in Hypertension and Dyslipidemia Management Activity No. 0217-0000-11-101-L01-P (Application-Based Activity) Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationLipid Metabolism Prof. Dr. rer physiol. Dr.h.c. Ulrike Beisiegel
Lipid Metabolism Department of Biochemistry and Molecular Biology II Medical Center Hamburg-ppendorf 1 Lipids. visceral fat. nutritional lipids 0 1.5 3 4.5 9 h. serum lipids. lipid accumulation in the
More informationCHOLESTAGEL 625 mg Genzyme
CHOLESTAGEL 625 mg Genzyme 1. NAME OF THE MEDICINAL PRODUCT Cholestagel 625 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 625 mg colesevelam hydrochloride (hereafter
More informationNovel Therapeutic Strategies in Lipid Management: Lowering LDL C to Improve Patient Outcomes
Novel Therapeutic Strategies in Lipid Management: Lowering LDL C to Improve Patient Outcomes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology University of Pennsylvania April 25,
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationDisclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values
39 th National Conference on Pediatric Health Care Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA March 19-22, 2018 CHICAGO Disclosures Speakers Bureau Sanofi and Regeneron Learning Objectives
More informationHi Lipidaholics: This week case is a very common lipid disorder, but what are the medications needed to achieve goals of therapy.
LIPID CASE 251 Treating HDL Size Hi Lipidaholics: This week case is a very common lipid disorder, but what are the medications needed to achieve goals of therapy. I was asked about a 44 year old physically
More informationROUNDTABLE DISCUSSION: CONTROLLING CHOLESTEROL WITH COMBINATION THERAPY
: CONTROLLING CHOLESTEROL WITH COMBINATION THERAPY The following are excerpts from a roundtable discussion with faculty chair Peter O. Kwiterovich, Jr, MD; James M. McKenney, PharmD; Donald Hunninghake,
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationCholesterol Metabolism
Cholesterol Metabolism Lippincott s Illustrated Review Chapter 18 Steroid Nucleus 1 2 Cholesterol was isolated from gall bladder stones in 1774 3 Sources and Elimination of Cholesterol Synthesis: 1000
More informationLipid Lowering in Patients at High Risk for Cardiovascular Disease
Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationHyperlipidemia. Intern Immersion Block 2015
Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu Welcome! Disclosures: royalties from book sales (not
More informationInternational Journal of Chemistry and Pharmaceutical Sciences
Available online at www.pharmaresearchlibrary.com Pharma Research Library International Journal of Chemistry and Pharmaceutical Sciences 2013, Vol.1 (2): 180-186 ISSN 2321-3132 Pharma Research Library
More informationCLINICAL IMPORTANCE OF LIPOPROTEINS
25 Hyperlipidemias CLINICAL IMPORTANCE OF LIPOPROTEINS Raised levels of low-density lipoprotein (LDL) cholesterol and low levels of high density lipoprotein (HDL) cholesterol are independent risk factor
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationTreatment of Atherosclerosis in 2007
Treatment of Atherosclerosis in 2007 Szilard Voros, M.D. Medical Director Cardiovascular MR and CT Piedmont Hospital, Piedmont Hospital Our Paradigm Genotype Phenotype Environment Atherosclerotic Disease
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.05 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationThe Pharmacists Role in Lipid Management
The Pharmacists Role in Lipid Management Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant Clinical Assistant Professor, Univ. of Maryland Learning Objectives 1. ENHANCE your understanding
More informationInhibition of PCSK9: The Birth of a New Therapy
Inhibition of PCSK9: The Birth of a New Therapy Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Disclosures Dr. Kastelein
More informationRegulating Hepatic Cellular Cholesterol
Under circumstances of cholesterol deficiency, Sterol Regulatory Element Binding Proteins (SREBPs) via binding to DNA nuclear response elements set off genomic production of proteins and enzymes that induce
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationInternational Journal of Research and Development in Pharmacy and Life Sciences. Research Article
International Journal of Research and Development in Pharmacy and Life Sciences Available online at http//www.ijrdpl.com February - March, 214, Vol. 3, No.2, pp 943-948 ISSN: 2278-238 Research Article
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationDyslipidemia. (Med-341)
Dyslipidemia (Med-341) Anwar A Jammah, MD, FRCPC, FACP, CCD, ECNU. Associate Professor of Medicine Consultant Medicine, Endocrinology, Thyroid Oncology Department of Medicine, King Saud University The
More informationNew opportunities for targeting. multiple lipid pathways. Michel FARNIER, DIJON, FRANCE
New opportunities for targeting multiple lipid pathways Michel FARNIER, DIJN, FRANCE Lipid lowering drug therapy 60s and 70s - nicotinic acid -resins 70s to 90s - fibrates the 90s - statins Coronary heart
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationColesevelam hydrochloride: a specifically engineered bile acid sequestrant
Future Lipidology ISSN: 1746-0875 (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/tlip19 Colesevelam hydrochloride: a specifically engineered bile acid sequestrant Padmini Manghat &
More informationChapter VIII: Dr. Sameh Sarray Hlaoui
Chapter VIII: Dr. Sameh Sarray Hlaoui Lipoproteins a Lipids are insoluble in plasma. In order to be transported they are combined with specific proteins to form lipoproteins: Clusters of proteins and lipids.
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More information13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:
CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationUpdate in Lipid Management. Rameshkumar Raman M.D. Endocrine Associates of The Quad Cities
Update in Lipid Management Rameshkumar Raman M.D. Endocrine Associates of The Quad Cities Low-Density Lipoprotein (LDL) Consists of Multiple Distinct Subclasses Differing in Size and Lipid Content* Association
More informationCholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia
Cholesterol metabolism Function Biosynthesis Transport in the organism Hypercholesterolemia - component of all cell membranes - precursor of bile acids steroid hormones vitamin D Cholesterol Sources: dietary
More informationCARDIOVASCULAR DISEASE WHAT IS IT? WHAT IS THE ROLE OF CHOLESTEROL? HOW CAN WE REDUCE RISK?
1 CARDIOVASCULAR DISEASE WHAT IS IT? WHAT IS THE ROLE OF CHOLESTEROL? HOW CAN WE REDUCE RISK? Perry J Weinstock, MD, F.A.C.C. Head, Division of Cardiovascular Disease Director of Clinical Cardiology Cooper
More informationVI.2 Elements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology This medicine is used to lower levels of total cholesterol, LDL cholesterol ( bad cholesterol), and fatty substances called triglycerides
More information